Explore

TrendlineTrendline
Eli Lilly Secures Two FDA Approvals and Major Drug Discovery Alliance

Eli Lilly Secures Two FDA Approvals and Major Drug Discovery Alliance

Eli Lilly Secures Two FDA Approvals and Major Drug Discovery Alliance
Rapid ReadRapid Read
Radiology Report Generation AI Market Projected to Reach $13.63 Billion by 2035, Driven by Rising Workload

Radiology Report Generation AI Market Projected to Reach $13.63 Billion by 2035, Driven by Rising Workload

The global radiology report generation AI market, valued at $2.01 billion in 2025, is projected to surge to $13.63 billion by 2035, exhibiting a Compound Annual Growth Rate (CAGR) of 21.1% from 2026 to 2035, according to Spherical Insights. This significant growth is primarily driven by the increasing adoption of AI for structured reporting, which helps standardize reports, reduce documentation time, and improve consistency. Key factors contributing to this expansion include the rising workload of radiologists, growing imaging volumes, and a shortage of radiologists. AI-powered tools analyze medical images and clinical information to create draft reports, summarize findings, and integrate with existing clinical workflows like PACS and RIS. North America currently dominates the market, holding 41.3% of the share in 2025, with the U.S. leading regional demand.
TrendlineTrendline
Telix Pharmaceuticals and ITM Announce Radiopharma Merger Valued at Up to $2.35 Billion

Telix Pharmaceuticals and ITM Announce Radiopharma Merger Valued at Up to $2.35 Billion

Telix Pharmaceuticals and ITM Announce Radiopharma Merger Valued at Up to $2.35 Billion
Rapid ReadRapid Read
Novo Nordisk Advances Connected Drug Delivery with Smart Insulin Pens

Novo Nordisk Advances Connected Drug Delivery with Smart Insulin Pens

Novo Nordisk, a global healthcare company headquartered in Denmark, is actively participating in the connected drug delivery devices market. The company offers smart insulin pens, specifically NovoPen 6 and NovoPen Echo Plus, which are designed to record injection time and dose information. This data is then transferred to compatible diabetes applications, providing users with a comprehensive overview of their insulin administration and treatment tracking. Furthermore, Novo Nordisk has collaborated with BIOCORP on Mallya, a smart add-on device for the FlexTouch insulin pen. This partnership aims to enhance connected injection capabilities and reinforce Novo Nordisk's commitment to digitally enabled insulin delivery solutions for individuals managing diabetes.
Rapid ReadRapid Read
Continuous Glucose Monitors Linked to Reduced Mortality and Cardiovascular Complications in Type 2 Diabetes Patients

Continuous Glucose Monitors Linked to Reduced Mortality and Cardiovascular Complications in Type 2 Diabetes Patients

New data presented at the European Association for the Study of Diabetes (EASD) indicates that continuous glucose monitoring (CGM) systems are associated with a significantly lower risk of death and cardiovascular complications in adults with Type 2 diabetes who use basal insulin. A large, real-world study, which included Abbott's Libre technology, found that CGM users had a 45% lower risk of death at 12 months and a 36% lower risk at 24 months compared to non-users. The study also observed a reduction in cardiovascular-related complications, including fewer recurrent events. This research evaluated nearly 28,000 adults with Type 2 diabetes on basal insulin in the U.S., employing a rigorous methodology designed to mimic a randomized clinical trial. Additionally, a separate French observational study involving over 253,000 Type 2 diabetes patients showed that using Libre technology nearly halved acute diabetes-event hospitalizations across various insulin and non-insulin therapies.
TrendlineTrendline
Novo Nordisk Secures $1.3 Billion Nanexa Deal for Long-Acting Drug Delivery Technology

Novo Nordisk Secures $1.3 Billion Nanexa Deal for Long-Acting Drug Delivery Technology

Novo Nordisk Secures $1.3 Billion Nanexa Deal for Long-Acting Drug Delivery Technology
TrendlineTrendline
Novo Nordisk Licenses Nanexa's PharmaShell Technology for Long-Acting GLP-1 Treatments

Novo Nordisk Licenses Nanexa's PharmaShell Technology for Long-Acting GLP-1 Treatments

Novo Nordisk Licenses Nanexa's PharmaShell Technology for Long-Acting GLP-1 Treatments
TrendlineTrendline
Novo Nordisk Sets Ambitious Pipeline Sales Target Exceeding $23 Billion by 2035

Novo Nordisk Sets Ambitious Pipeline Sales Target Exceeding $23 Billion by 2035

Novo Nordisk Sets Ambitious Pipeline Sales Target Exceeding $23 Billion by 2035
Rapid ReadRapid Read
GLP-1 Drug Discontinuation Linked to Increased Cardiovascular Risk in Type 2 Diabetes Patients

GLP-1 Drug Discontinuation Linked to Increased Cardiovascular Risk in Type 2 Diabetes Patients

A three-year follow-up study conducted by researchers at Washington University in St. Louis School of Medicine, published in the international journal BMJ Medicine, indicates that discontinuing GLP-1-based obesity and diabetes treatments significantly increases the risk of heart attack and stroke. The study, which involved approximately 333,000 patients with type 2 diabetes, found that those who stopped GLP-1 treatment experienced a rapid loss of the cardiovascular protection effects provided by the drugs. Patients who ceased GLP-1 treatment for two years had a 22% higher risk of major cardiovascular events, including heart attack, stroke, and death, compared to those who continued the medication. Even a temporary hiatus of at least six months in dosing resulted in a reduced cardiovascular risk reduction (12%) compared to consistent treatment (18%). The study highlights a 'metabolic yo-yo' effect, where the benefits of the drug diminish quickly upon cessation, leading to a worsening of blood pressure, chol...
TheStreetTheStreet
91-year-old investor sees healthcare titan doubling in 3 years

91-year-old investor sees healthcare titan doubling in 3 years

The billionaire Home Depot co-founder has held the stock since 1977. Here's where he thinks it's going.
USA TodayUSA Today
TrumpRx claims the world's lowest drug prices. A new report raises doubts

TrumpRx claims the world's lowest drug prices. A new report raises doubts

KFF's analysis of 32 brand name drugs found TrumpRx's claim of big discounts compared to peer nations delivered mixed results.
TrendlineTrendline
Latham Watkins Advises on ADARx Pharmaceuticals' Upsized US$446.3 Million Initial Public Offering

Latham Watkins Advises on ADARx Pharmaceuticals' Upsized US$446.3 Million Initial Public Offering

Latham Watkins Advises on ADARx Pharmaceuticals' Upsized US$446.3 Million Initial Public Offering